Exforge

Exforge is a brand name of amlodipine/valsartan, approved by the FDA in the following formulation(s):

EXFORGE (amlodipine besylate; valsartan - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: June 20, 2007
  
  Strength(s): EQ 10MG BASE;160MG ^[RLD], EQ 10MG BASE;320MG ^[RLD], EQ 5MG BASE;160MG, EQ 5MG BASE;320MG
  

Has a generic version of Exforge been approved?

No. There is currently no therapeutically equivalent version of Exforge available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exforge. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Acyl compounds
  Patent 5,399,578
  Issued: March 21, 1995
  Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
  Assignee(s): Ciba-Geigy Corp
  Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
  
  Patent expiration dates:
  
  
  • March 21, 2012
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 21, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Solid oral dosage forms of valsartan
  Patent 6,294,197
  Issued: September 25, 2001
  Inventor(s): Wagner; Robert Frank & Katakuse; Yoshimitsu & Taike; Takashi & Yamato; Fujiki & Kohlmeyer; Manfred
  Assignee(s): Novartis AG
  The present invention is concerned with solid dosage forms comprising a) valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
  
  Patent expiration dates:
  
  
  • June 18, 2017
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  
  
  • December 18, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method of treatment and pharmaceutical composition
  Patent 6,395,728
  Issued: May 28, 2002
  Inventor(s): Randy Lee; Webb & Marc; de Gasparo
  Assignee(s): Novartis AG
  The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae, supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or ustable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetessecondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy,glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), and stroke, comprising administering a therapeutically effective amount of combination of (i) the AT1-antagonists valsartan or a pharmaceutically acceptable salt thereof and (ii) a Calcium channel blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment and to corresponding pharmaceutical combination composition.
  
  Patent expiration dates:
  
  
  • July 8, 2019
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 23, 2011 - INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
  
  

See also...

• Exforge Consumer Information (Drugs.com)
• Exforge Consumer Information (Wolters Kluwer)
• Exforge Consumer Information (Cerner Multum)
• Exforge Advanced Consumer Information (Micromedex)
• Amlodipine/Valsartan Consumer Information (Wolters Kluwer)
• Amlodipine and valsartan Consumer Information (Cerner Multum)
• Amlodipine and valsartan Advanced Consumer Information (Micromedex)